Department of Chemical Biology & Therapeutics, St. Jude Children's Research Hospital, 262 Danny Thomas Place, Memphis, TN 38105, USA.
Department of Chemical Biology & Therapeutics, St. Jude Children's Research Hospital, 262 Danny Thomas Place, Memphis, TN 38105, USA; Integrated Biomedical Sciences Program, University of Tennessee Health Science Center, 920 Madison Avenue, Memphis, TN 38163, USA.
Biochem Pharmacol. 2018 Jun;152:211-223. doi: 10.1016/j.bcp.2018.03.029. Epub 2018 Mar 31.
The constitutive androstane receptor (CAR) and pregnane X receptor (PXR) are xenobiotic sensors that regulate the expression of drug-metabolizing enzymes and efflux transporters. CAR activation promotes drug elimination, thereby reducing therapeutic effectiveness, or causes adverse drug effects via toxic metabolites. CAR inhibitors could be used to attenuate these adverse drug effects. CAR and PXR share ligands and target genes, confounding the understanding of the regulation of receptor-specific activity. We previously identified a small-molecule inhibitor, CINPA1, that inhibits CAR (without activating PXR at lower concentrations) by altering CAR-coregulator interactions and reducing CAR recruitment to DNA response elements of regulated genes. However, solid evidence was not presented for the direct binding of CINPA1 to CAR. In this study, we demonstrate direct interaction of CINPA1 with the CAR ligand-binding domain (CAR-LBD) and identify key residues involved in such interactions through a combination of biophysical and computational methods. We found that CINPA1 resides in the ligand-binding pocket to stabilize the CAR-LBD in a more rigid, less fluid state. Molecular dynamics simulations, together with our previously reported docking model, enabled us to predict which CAR residues were critical for interactions with CINPA1. The importance of these residues for CINPA1 binding were then validated by directed mutations and testing the mutant CAR proteins in transcription reporter and coregulatory interaction assays. We demonstrated strong hydrogen bonding of CINPA1 with N165 and H203 and identified other residues involved in hydrophobic contacts with CINPA1. Overall, our data confirm that CINPA1 directly binds to CAR.
组成型雄烷受体 (CAR) 和孕烷 X 受体 (PXR) 是两种外来生物传感器,可调节药物代谢酶和外排转运蛋白的表达。CAR 的激活可促进药物消除,从而降低治疗效果,或通过有毒代谢物引起不良药物作用。CAR 抑制剂可用于减轻这些不良药物作用。CAR 和 PXR 共享配体和靶基因,这使得理解受体特异性活性的调节变得复杂。我们之前发现了一种小分子抑制剂 CINPA1,它通过改变 CAR-共激活因子相互作用并减少 CAR 募集到受调节基因的 DNA 反应元件,从而抑制 CAR(在较低浓度下不激活 PXR)。然而,并没有直接证明 CINPA1 与 CAR 的结合。在这项研究中,我们通过结合生物物理和计算方法,证明了 CINPA1 与 CAR 配体结合域 (CAR-LBD) 的直接相互作用,并确定了参与这种相互作用的关键残基。我们发现 CINPA1 位于配体结合口袋中,可将 CAR-LBD 稳定在更刚性、流动性更低的状态。分子动力学模拟,以及我们之前报道的对接模型,使我们能够预测哪些 CAR 残基对于与 CINPA1 的相互作用至关重要。然后,通过定向突变和在转录报告基因和共激活因子相互作用测定中测试突变型 CAR 蛋白,验证了这些残基对 CINPA1 结合的重要性。我们证明了 CINPA1 与 N165 和 H203 之间的强氢键,并确定了其他涉及与 CINPA1 疏水接触的残基。总的来说,我们的数据证实 CINPA1 直接与 CAR 结合。